Skip to content
StockMarketAgent
Direct answer
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Stock analysis

ZTS fair value $109–$170

By StockMarketAgent.AI team· supervised by
Analizado: 2026-05-12Próxima actualización: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Precio
$76.94
▲ +62.83 (+81.66%)
Valor razonable
$140
$109–$170
Calificación
Compra fuerte
confidence 88/100
Potencial alcista
+81.7%
upside to fair value
Margen de seguridad
$118.80
MoS level · 15%
Capitalización bursátil
$32.3B
P/E fwd 10.3
Respaldo en inglésES
Mostrando la fuente en inglés mientras traducimos
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.

§1 Resumen ejecutivo

  • Composite fair value $140 with high case $170.
  • Implied upside of 81.7% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$76.94Price
Low $109.15
Mid $139.77
High $170.49

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.

  • Intangible assets via unmatched patent
    Intangible assets via unmatched patent portfolio and brand loyalty.
  • High switching costs for veterinary
    High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
  • Cycle upside
    Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.

§2 Caso bajista

A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.

Cómo puede fallar esta tesis

Margin Contraction

· Low

Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.

FV impact
Valuation compresses to the $109.15 low-end threshold.

Livestock Headwinds

· Medium

Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.

FV impact
Mild drag on terminal value generation and forward EPS.

Macro Demand Shock

· Medium

Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.

FV impact
Near-term EPS shock testing the $110 forward earnings scenario value.
Señales de alerta temprana a vigilar
MétricaActualUmbral de activación
Operating margin contracting below 35% over two consecutive quarters.MonitorDeterioration versus the report thesis
Forward EPS growth turning negative.MonitorDeterioration versus the report thesis
ROIC dropping precipitously toward the 8.43% WACC.MonitorDeterioration versus the report thesis
Erosion of the 71.8% gross margin floor.MonitorDeterioration versus the report thesis
Accelerated generic approvals targeting core parasiticide or dermatology portfolios.MonitorDeterioration versus the report thesis

§3 Historial financiero

Cuenta de resultados — últimos seis períodos

Concepto2022-12-312023-12-312024-12-312025-12-31Trend
Ingresos$8.08B$8.54B+5.7%$9.26B+8.4%$9.47B+2.3%+5.4%
Beneficio bruto$5.63B$5.98B$6.54B$6.80B+6.5%
Beneficio operativo$2.93B$3.07B$3.39B$3.60B+7.1%
Beneficio neto$2.11B$2.34B+10.9%$2.49B+6.4%$2.67B+7.2%+8.1%
BPA (diluido)$4.49$5.07$5.47$6.02+10.3%
EBITDA$3.34B$3.67B$3.86B$4.07B+6.8%
I+D$539.0M$614.0M$686.0M$698.0M+9.0%
SG&A$2.01B$2.15B$2.32B$2.38B+5.8%

Puntuaciones de calidad

OCF / Beneficio neto
1.09×
>1 indica alta calidad de los beneficios
Umbral de calidad contable
Fail
Umbral ajustado por sector
ROIC
22.5%
Rentabilidad del capital invertido
Suscriptores individuales — desde §411 secciones más

Leer el análisis completo — 11 secciones más.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Informe completo para cada ticker cubierto
24 meses de archivo de calificaciones
Briefings de lista de seguimiento + alertas de cambio de calificación
Exportación PDF + DOCX en cualquier idioma
Comenzar prueba gratuita
Cancela cuando quieras.
BALANCE SHEET FAQ

ZTS balance sheet questions

  1. ZTS (ZTS)'s balance sheet section reports total assets, total liabilities, shareholders' equity, and the structure of debt versus cash so leverage and liquidity can be read directly.
FAQ

ZTS — frequently asked questions

  1. Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Related coverage

Names readers of ZTS also follow

Same archetype: mature-compounder